Mylan may have overcharged taxpayers by $1.27 billion for EpiPens, HHS says

Mylan may have overcharged taxpayers as much as $1.27 billion over 10 years for its signature EpiPens, according to an analysis released Wednesday by the Department of Health and Human Services's watchdog. The pharmaceutical company has been in hot water for potentially misclassifying their signature epinephrine auto-injector in a way that enabled it to charge a…